Elravie Premier Light-L
$40.00
Elravie fillers and biorevitalizants are manufactured by the South Korean high-tech company Humedix. Thanks to constant research and bioengineering, the company produces advanced cosmetic products that meet international quality standards.
Elravie Premier is a monophasic dermal filler based on hyaluronic acid of non-animal origin, created using HI technology. The technology consists of the activation of HA molecules, in which the greatest number of bonds between the molecules of HA and BDDE is formed during crosslinking process. This leads to decrease in the amount of residual BDDE and formation of a stable filler structure. Therefore, risk of edema and allergic reaction after the procedure is significantly reduced.Description
Elravie is a monophasic dermal filler created using HI technology. A unique technology consists in the activation of hyaluronic acid molecules, resulting in the formation of the largest number of compounds HA molecules with BDDE in the crosslinking process. So, the amount of residual BDDE is significantly reduced, and a fairly stable gel structure is formed.
Elravie fillers received the Jang Young-Sil Award in 2014 and the Consumer’s Choice Filler Award in 2016.
Strengths of Elravie:
- safety and quality
- highly purified hyaluronic acid
- natural effect
- stable form of the product’s composition
- long-term effect
- popularity of filler among cosmetologists and patients
Elravie Premier Light-L is ideal for the treatment of superficial skin defects.
Scope of Elravie Premier Light-L:
- correction of fine perioral wrinkles, “crow’s feet”, wrinkles on the forehead and between the eyebrows
- lip shape and volume correction
- neckline bio-reinforcement
The aesthetic effect lasts 9-12 months.
Product composition: HA 23 mg/ml, Lidocaine 0.3%
Elravie Premier Light-L
1 syringe × 1.0 ml per pack
Needle: 30G
Manufacturer: Humedix Co., Ltd., South Korea
Additional information
| Weight | 0.1 kg |
|---|---|
| Origin | South Korea |
| Ingredients |
Reviews
There are no reviews yet.